Kenneth S. Cohen
YOU?
Author Swipe
View article: A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL Open
In patients with diffuse large B-cell lymphoma (DLBCL), concurrent deregulation of MYC and BCL2 confers inferior outcomes following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). DA–EPOCH-R (dose-adjusted e…
View article: Supplementary Table 1 from Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers
Supplementary Table 1 from Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers Open
PDF file - 66K, This table contains the detailed immunohistochemical data scoring depicted in Figure A and B
View article: Supplementary Figures 1-7 from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy
Supplementary Figures 1-7 from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy Open
Supplementary Figures 1-7 from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy
View article: Data from Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers
Data from Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers Open
Esophageal cancer incidence is increasing and has few treatment options. In studying receptor tyrosine kinases associated with esophageal cancers, we have identified EPHB4 to be robustly overexpressed in cell lines and primary tumor tissue…
View article: Data from Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers
Data from Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers Open
Esophageal cancer incidence is increasing and has few treatment options. In studying receptor tyrosine kinases associated with esophageal cancers, we have identified EPHB4 to be robustly overexpressed in cell lines and primary tumor tissue…
View article: Supplementary Figures 1-7 from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy
Supplementary Figures 1-7 from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy Open
Supplementary Figures 1-7 from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy
View article: Supplementary Table 1 from Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers
Supplementary Table 1 from Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers Open
PDF file - 66K, This table contains the detailed immunohistochemical data scoring depicted in Figure A and B
View article: Data from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy
Data from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy Open
Most cancer patients receive radiotherapy during the course of their disease. Improvements in the therapeutic index have been based mainly on physical improvements in delivery, as radiosensitizer development to target tumor cells has yet t…
View article: Data from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy
Data from Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy Open
Most cancer patients receive radiotherapy during the course of their disease. Improvements in the therapeutic index have been based mainly on physical improvements in delivery, as radiosensitizer development to target tumor cells has yet t…
View article: Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age
Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age Open
OBJECTIVE: To evaluate associations between use of seven progestogens and incident acute venous thromboembolism (VTE) among women of reproductive age. METHODS: This nested matched case–control study identified women aged 15–49 years from J…
View article: Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas Open
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects …
View article: Refractory vaccine-induced thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE)
Refractory vaccine-induced thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE) Open
Vaccine-induced thrombotic thrombocytopenia (VITT) is a newly-described hematologic disorder which presents as acute thrombocytopenia and thrombosis after administration of adenovirus-based vaccines against COVID-19. Due to positive assays…
View article: Abstract No. 670 Safety and efficacy of mechanical inferior vena cava filtration for preventing pulmonary embolism in high-risk orthopedic patients undergoing total hip or knee arthroplasty
Abstract No. 670 Safety and efficacy of mechanical inferior vena cava filtration for preventing pulmonary embolism in high-risk orthopedic patients undergoing total hip or knee arthroplasty Open
View article: Phase 1 study of lenalidomide plus dose‐adjusted EPOCH‐R in patients with aggressive B‐cell lymphomas with deregulated MYC and BCL2
Phase 1 study of lenalidomide plus dose‐adjusted EPOCH‐R in patients with aggressive B‐cell lymphomas with deregulated MYC and BCL2 Open
Background Dual translocation of MYC and BCL2 or the dual overexpression of these proteins in patients with aggressive B‐cell lymphomas (termed double‐hit lymphoma [DHL] and double‐expressor lymphoma [DEL], respectively) have poor outcomes…
View article: High-Grade CD5-Positive Follicular Lymphoma With Hyaline-Vascular Castleman Disease–Like Follicles
High-Grade CD5-Positive Follicular Lymphoma With Hyaline-Vascular Castleman Disease–Like Follicles Open
Follicular lymphoma (FL) with hyaline-vascular Castleman disease–like follicles is a very rare variant of follicular lymphoma. To the best of our knowledge, they are not reported to be positive for CD5. We report a rare case of grade 3B FL…
View article: University of Chicago phase II consortium trial of selumetinib (<scp>MEK</scp>i) demonstrates low tolerability and efficacy in relapsed DLBCL
University of Chicago phase II consortium trial of selumetinib (<span>MEK</span>i) demonstrates low tolerability and efficacy in relapsed DLBCL Open
Despite significant advances in the treatment of diffuse large B-cell lymphoma (DLBCL), up to 40% of patients relapse following standard chemoimmunotherapy. Haematopoietic stem cell transplantation (HSCT) may cure a minority of relapsed pa…
View article: Proof of Concept for a Novel Curriculum: Learning a Second Language during Anesthesiology Residency
Proof of Concept for a Novel Curriculum: Learning a Second Language during Anesthesiology Residency Open
This article describes a novel curriculum for anesthesiology residents matriculating through Brigham and Women's Department of Anesthesiology. It is offered electively and provides physician residents with time to acquire language skills t…